EGFR and non-small cell lung carcinoma: Additionally, more studies may help determine if PLR should be considered as a reliable outcome predictor in EGFR mutant NSCLC patients receiving TKIs and to better understand trends in peripheral cell counts in patients treated with 3rd generation EGFR TKIs.